BeOne Medicines (ONC) Long-Term Debt Repayments (2018 - 2026)
BeOne Medicines (ONC) posted quarterly Long-Term Debt Repayments of $7.6 million for Q1 2026, up 81.28% year-over-year from $4.2 million in Q1 2025, and down 47.73% quarter-over-quarter from $14.6 million in Q4 2025.
BeOne Medicines (ONC) Long-Term Debt Repayments (2018 - 2026) Analysis & Trends
BeOne Medicines (ONC) has reported Long-Term Debt Repayments for 6 consecutive years, with $7.6 million the latest figure, recorded in Q1 2026.
- In Q1 2026, Long-Term Debt Repayments rose 81.28% year-over-year to $7.6 million; the TTM figure through Mar 2026 stood at $39.1 million (up 36.41% YoY), while the FY2025 annual figure was $35.7 million, up 27.29% from the prior year.
- Long-Term Debt Repayments slipped to $7.6 million in Q1 2026 per ONC's latest filing, from $14.6 million in the prior quarter.
- Across five years, Long-Term Debt Repayments topped out at $14.6 million in Q4 2025 and bottomed at $1.5 million in Q1 2023.
- Historically, Long-Term Debt Repayments has averaged $6.9 million across 4 years, with a median of $5.2 million in 2023.
- On a YoY basis, Long-Term Debt Repayments climbed as much as 199.77% in 2024 and fell as far as 57.92% in 2024.
- BeOne Medicines' Long-Term Debt Repayments stood at $5.2 million in 2023, then jumped by 99.89% to $10.4 million in 2024, then jumped by 39.89% to $14.6 million in 2025, then plunged by 47.73% to $7.6 million in 2026.
- Business Quant data shows ONC's Long-Term Debt Repayments at $7.6 million in Q1 2026, $14.6 million in Q4 2025, and $4.3 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Long-Term Debt Repayments (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | - |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 17.05 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | - |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | - |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | - |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | - |
| 10 | Roivant Sciences | 26.16 Bn | 26.85 Bn | 1.16 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 17.05 Mn |
| Jun 30, 2026 | 17.05 Mn |
| Mar 31, 2026 | 7.64 Mn |
| Mar 31, 2026 | 7.64 Mn |
| Dec 31, 2025 | 14.62 Mn |
| Dec 31, 2025 | 14.62 Mn |
| Sep 30, 2025 | 4.26 Mn |
| Sep 30, 2025 | 4.26 Mn |
| Jun 30, 2025 | 12.58 Mn |
| Jun 30, 2025 | 12.58 Mn |
| Mar 31, 2025 | 4.22 Mn |
| Mar 31, 2025 | 4.22 Mn |
| Dec 31, 2024 | 10.45 Mn |
| Dec 31, 2024 | 10.45 Mn |
| Sep 30, 2024 | 3.56 Mn |
| Sep 30, 2024 | 3.56 Mn |
| Jun 30, 2024 | 10.44 Mn |
| Jun 30, 2024 | 10.44 Mn |
| Mar 31, 2024 | 3.58 Mn |
| Mar 31, 2024 | 3.58 Mn |